On May 1, 2020 Johan Liwing, from Janssen (Johnson & Johnson), reported that it has been appointed new acting CEO at XNK Therapeutics. He is succeeding the former CEO Karin Mellström whom will retire, but remain disposable for the the company as Project Manager (Press release, CellProtect Nordic Pharmaceuticals, MAY 1, 2020, View Source [SID1234560777]). Johan Liwing has over 15 year’s of experience from leading positions within the Life science industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he has held various positions in health economics, sales & marketing, as well as observational research. In his most recent position at Janssen, as global senior director, he was responsible for the development and use of observational data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!